CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 30 enrolled
Drug / intervention
Medroxyprogesterone progesterone acetate (MPA) +1 moredrug
Likely dose
Medroxyprogesterone progesterone acetate (MPA) 1000 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00577122
NCT00577122Phase 2Completed
CompareCT.gov

MPA Revisited: A Phase II Study of Anti-Metastatic, Anti-Angiogenic Therapy in Postmenopausal Patients With Hormone Receptor Negative Breast Cancer. A Translational Breast Cancer Research Consortium (TBCRC) Trial

Indiana University·interventional·Posted Dec 19, 2007·Updated Oct 16, 2023

In Brief

A Phase 2 clinical trial evaluating Medroxyprogesterone progesterone acetate (MPA) and Medroxyprogesterone with Cyclophosphamide + Methotrexate for Estrogen Receptor-negative Breast Cancer and 3 related conditions. Completed, enrolled 30 participants across 7 sites.

Detailed Summary

The purpose of this study is to evaluate the impact of MPA alone and in combination with low dose oral chemotherapy in patients with ER- and PR- advanced breast cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEstrogen Receptor-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
CountriesUnited States
CollaboratorsTranslational Breast Cancer Research Consortium

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 19, 2007
Enrollment StartJul 1, 2007
Primary CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 18.5 years ago

Interventions

Medroxyprogesterone progesterone acetate (MPA)drug

1000 mg po daily

Medroxyprogesterone with Cyclophosphamide + Methotrexatedrug

Medroxyprogesterone Acetate Dose 1000 mg po daily Cyclophosphamide Dose 50 mg po daily Methotrexate Dose 2.5 mg po daily Days 1 and 2 of each week